The United Kingdom and the United States have signed a key bilateral deal that will maintain no tariffs on UK pharmaceutical exports entering the American market.
The Terms of the Pact
In exchange for the tariff guarantee, the UK has agreed to increase spending on drugs through the National Health Service (NHS). This pledge guarantees that tariffs on these vital goods will remain at zero for a timeframe of three years.
This agreement is in response to previous warnings to significantly raise import taxes on patented pharmaceutical imports, with increases floated up to double the cost.
"This deal with the Britain bolsters the international landscape for new treatments and establishes long-overdue equity to U.S.–U.K. drug exports," an announcement said.
Commercial Impact
Pharmaceuticals represent one of the UK's largest goods shipped to the United States, which is clearly the biggest buyer for large UK drugmakers.
Statistics indicate that in the year leading up to September, the UK exported medicines valued at billions to the US. This figure represented 17.4% of all goods exports in that span.
"This guarantee safeguards employment, stimulates capital expenditure and sets the stage for the UK to become a global hub for biotech and pharma," a government official commented.
Detailed UK Commitments
The pact includes several notable changes from the UK:
- Higher Cost Ceiling: The UK will lift the affordability limit at which it judges new therapies to be unaffordable by a quarter.
- Higher Drug Budget: There is a aim to double overall health service expenditure on drugs from 0.3 percent of Gross Domestic Product to 0.6 percent over the next decade.
- Rebate Cap: The amount pharmaceutical firms must return to the NHS to stay within budget will be limited at fifteen percent. Last year, repayments topped 20%.
Recent Tensions
The deal takes place against a long-running dispute between the drug companies and the UK government over drug pricing and approval rates.
These tensions were intensified by claims that US customers were paying a premium for the same drugs than people in the other developed nations.
Recently, several significant drug company projects in the UK have been halted or scrapped, while multi-billion-dollar investments have been pledged toward US facilities.
One official publicly accepted that the NHS had to spend more on drugs, noting that its spending on drugs had decreased as a proportion of its resources over the last ten years.
